Form 4: TOI CEO Daniel Virnich Acquires Shares via RSU Vesting
Insider Transaction Report
The Oncology Institute CEO Daniel Virnich acquired 6,211 shares of common stock through vested RSU awards.
Summary
- Daniel Virnich, Chief Executive Officer of The Oncology Institute, Inc. (TOI), acquired 6,211 shares of common stock.
- The transaction occurred on November 12, 2025, and the shares were acquired at a price of $0.00 per share.
- These shares represent Restricted Stock Unit (RSU) awards that were fully vested upon grant, net of withholding tax obligations.
- Following this transaction, Daniel Virnich directly beneficially owns a total of 1,793,520 shares of common stock.
- The Form 4 filing was signed on November 14, 2025.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While a routine RSU vesting, it still represents an increase in direct insider ownership, which is generally viewed favorably as it aligns management's interests with shareholders. However, it's not a cash purchase, which would typically carry a stronger positive signal.
Positives
- The acquisition of shares by the CEO increases insider ownership, which can signal management's confidence in the company's future prospects.
- The shares were acquired through the vesting of Restricted Stock Units, aligning executive compensation with shareholder value.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
Insider transactions, such as RSU vestings, are common occurrences in publicly traded companies. While this specific transaction is routine, an increase in insider ownership can be viewed by the market as a positive signal, indicating management's continued alignment with shareholder interests in the healthcare services sector.
Stakeholder Impact
- Shareholders may view the increase in CEO ownership as a positive sign of management's commitment and confidence in the company's long-term value.
Key Dates
| Date | Description |
|---|---|
| 11/12/2025 | Date of transaction where 6,211 shares of common stock were acquired. |
| 11/14/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
The Oncology Institute, TOI, Daniel Virnich, CEO, Insider Trading, Form 4, Stock Acquisition, RSU Vesting, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.